商业抗体检测法可检出BNT162b2与mRNA-1273疫苗诱导的SARS-CoV-2抗体
该队列研究纳入225名接种BNT162b2或mRNA-1273的医护人员和长期护理机构居民,用四种商业试剂检测疫苗诱导抗体。所有抗刺突蛋白检测法均能在接种后检出抗体,且随时间增加;第二剂前73-89%个体可检出中和抗体。
要点
- 商业高通量血清学检测可检出mRNA疫苗诱导的抗刺突蛋白IgG。
- 接种后抗刺突蛋白抗体水平随时间显著上升。
- 第二剂前73-89%接种者已产生可检测的中和抗体。
核心结论
- 商业高通量检测法可检出mRNA疫苗诱导的SARS-CoV-2抗刺突蛋白IgG,且抗体水平随时间增加。
研究设计与样本
- 队列研究,纳入225名参与者(177名接种BNT162b2的医护人员和48名接种mRNA-1273的长期护理机构居民),中位年龄41岁,66-78%为女性。
主要发现
- BNT162b2组基线时4.1%检出核衣壳IgG,mRNA-1273组首剂后2周21.9%检出核衣壳IgG。
- 所有抗刺突蛋白检测法在接种后均检出抗体,BNT162b2组第一至最后采样点平均增幅87.2%(范围73.8-94.3%),mRNA-1273组平均增幅25.2%(范围23.8-26.7%),均p<0.05。
- 两种疫苗所有接种后时间点均检出中和抗体,滴度随时间增加(均p<0.05)。
- 第二剂接种前,73-89%个体可检出中和抗体。
关键数值与推荐
- 使用四种商业试剂:Abbott SARS-CoV-2 IgG、Abbott SARS-CoV-2 IgG II Quant、DiaSorin Trimeric S IgG和GenScript cPASS检测疫苗诱导抗体。
临床怎么用
- 商业高通量血清学检测可用于评估mRNA疫苗接种后的抗体反应。
- 第二剂前多数接种者已产生中和抗体,提示部分保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With rapid approval of SARS-CoV-2 vaccines, the ability of clinical laboratories to detect vaccine-induced antibodies with available high-throughput commercial assays is unknown. We aimed to determine if commercial serology assays can detect vaccine-induced antibodies (VIAs) and understand the vaccination response. METHODS: This cohort study recruited healthcare workers and residents of long-term care facilities (receiving the BNT162b2 and mRNA-1273 products, respectively) who underwent serum collection pre-vaccination (BNT162b2 group), 2-weeks post vaccination (both groups), and pre-2nd dose (both groups). Sera were tested for the presence of SARS-CoV-2 IgG using four commercial assays (Abbott SARS-CoV-2 IgG, Abbott SARS-CoV-2 IgG II Quant, DiaSorin Trimeric S IgG, and GenScript cPASS) to detect VIAs. Secondary outcomes included description of post-vaccination antibody response and correlation with neutralizing titers. RESULTS: 225 participants (177 receiving BNT162b2 and 48 receiving mRNA-1273) were included (median age 41 years; 66-78% female). Nucleocapsid IgG was found in 4.1% and 21.9% of the BNT162b2 (baseline) and mRNA-1273 (2-weeks post first dose). All anti-spike assays detected antibodies post-vaccination, with an average increase of 87.2% (range 73.8-94.3%; BNT162b2), and 25.2% (range 23.8-26.7%; mRNA-1273) between the first and last sampling time points (all p < 0.05). Neutralizing antibodies were detected at all post-vaccine timepoints for both vaccine arms, with increasing titers over time (all p < 0.05). CONCLUSIONS: Anti-spike vaccine-induced SARS-CoV-2 IgG are detectable by commercially available high-throughput assays and increases over time. Prior to second dose of vaccination, neutralizing antibodies are detectable in 73-89% of individuals, suggesting most individuals would have some degree of protection from subsequent infection.
引用
- Kanji JN, Bailey A, Fenton J, et al. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests. Vaccine. 2021. PMID: 34454782. doi:10.1016/j.vaccine.2021.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。